The molecular biology of chronic myeloid leukemia

Michael W. Deininger(Hammersmith Hospital), John M. Goldman(Hammersmith Hospital), Junia V. Melo(Hammersmith Hospital)
Blood
November 15, 2000
10.1182/blood.v96.10.3343
Cited by 1,616

Abstract

Chronic myeloid leukemia (CML) is probably the most extensively studied human malignancy. The discovery of the Philadelphia (Ph) chromosome in 19601 as the first consistent chromosomal abnormality associated with a specific type of leukemia was a breakthrough in cancer biology. It took 13 years

Related Papers

The Tyrosine Kinase Inhibitor CGP57148B Selectively Inhibits the Growth of BCR-ABL–Positive Cells
Michael W. Deininger, John M. Goldman, Nicholas Lydon et al.|Blood|1997|626
Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia
A Bedi, BA Zehnbauer, James Barber et al.|Blood|1994|498
The Presence of Typical and Atypical BCR-ABL Fusion Genes in Leukocytes of Normal Individuals: Biologic Significance and Implications for the Assessment of Minimal Residual Disease
Shikha Bose, Michael W. Deininger, Joanna Góra‐Tybor et al.|Blood|1998|457
Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells
T Skórski, Palanisamy Kanakaraj, Margaret Nieborowska-Skorska et al.|Blood|1995|410
c‐Abl kinase regulates the protein binding activity of c‐Crk.
S.M. Feller, Beatrice S. Knudsen, Hidesaburô Hanafusa|The EMBO Journal|1994|366